Cerus announces FDA approval on BLA for interstate distribution of blood
Cerus announced that the Community Blood Center, or CBC of Appleton, Wisconsin received approval by the FDA on their Biologics License Application, or BLA, requesting allowance of interstate distribution of platelets that have been pathogen-reduced with the Intercept Blood System. CBC is the fourth blood center to receive BLA approval. Six additional blood centers are awaiting BLA approvals. The BLA is a common procedure for blood centers to request permission from FDA to introduce a biologic product into interstate commerce. Until a blood center obtains a BLA, they are restricted to distributing Intercept-treated products to hospitals within the state in which they are produced. While some blood centers may distribute primarily in-state, many U.S. blood centers have extensive interstate distribution.